Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

1.

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

Busch S, Sims AH, Stål O, Fernö M, Landberg G.

Cancer Res. 2015 Apr 1;75(7):1457-69. doi: 10.1158/0008-5472.CAN-14-1583.

PMID:
25833830
2.

Gene expression profiling reveals biological pathways responsible for phenotypic heterogeneity between UK and Sri Lankan oral squamous cell carcinomas.

Saeed AA, Sims AH, Prime SS, Paterson I, Murray PG, Lopes VR.

Oral Oncol. 2015 Mar;51(3):237-46. doi: 10.1016/j.oraloncology.2014.12.004. Epub 2015 Jan 2.

PMID:
25560800
3.

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM.

Breast Cancer Res Treat. 2014 Aug;147(1):211-9. doi: 10.1007/s10549-014-3080-x. Epub 2014 Aug 9.

PMID:
25104442
4.

Molecular changes in lobular breast cancers in response to endocrine therapy.

Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, Kay C, Thomas JS, Dixon JM, Sims AH.

Cancer Res. 2014 Oct 1;74(19):5371-6. doi: 10.1158/0008-5472.CAN-14-0620. Epub 2014 Aug 6.

PMID:
25100562
5.

Increased STAT1 signaling in endocrine-resistant breast cancer.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP.

PLoS One. 2014 Apr 11;9(4):e94226. doi: 10.1371/journal.pone.0094226. eCollection 2014.

6.

Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2.

Gray TA, Alsamman K, Murray E, Sims AH, Hupp TR.

Mol Biosyst. 2014 Jun;10(6):1409-25. doi: 10.1039/c4mb00113c. Epub 2014 Apr 7.

PMID:
24710632
7.

A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.

Ablett MP, O'Brien CS, Sims AH, Farnie G, Clarke RB.

Oncotarget. 2014 Feb 15;5(3):599-612.

8.

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Lehn S, Tobin NP, Sims AH, Stål O, Jirström K, Axelson H, Landberg G.

BMC Cancer. 2014 Feb 22;14:119. doi: 10.1186/1471-2407-14-119.

9.

Modulation of strain-specific differences in gene expression by cannabinoid type 2 receptor deficiency.

Sophocleous A, Sims AH, Idris AI, Ralston SH.

Calcif Tissue Int. 2014 Apr;94(4):423-32. doi: 10.1007/s00223-013-9823-6. Epub 2013 Dec 27.

PMID:
24370613
10.

Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.

Keune WJ, Sims AH, Jones DR, Bultsma Y, Lynch JT, Jirström K, Landberg G, Divecha N.

Cancer Res. 2013 Dec 1;73(23):6913-25. doi: 10.1158/0008-5472.CAN-13-0424. Epub 2013 Oct 14.

11.

Use of microarray analysis to investigate EMT gene signatures.

Sims AH, Larionov AA, Harrison DJ, Katz E.

Methods Mol Biol. 2013;1046:85-95. doi: 10.1007/978-1-62703-538-5_5.

PMID:
23868583
12.

Wnt pathway activity in breast cancer sub-types and stem-like cells.

Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB.

PLoS One. 2013 Jul 4;8(7):e67811. doi: 10.1371/journal.pone.0067811. Print 2013.

13.

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C.

PLoS One. 2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. Epub 2013 Jan 2.

14.

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.

Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP, Langdon SP.

Endocr Relat Cancer. 2013 Feb 18;20(1):123-36. doi: 10.1530/ERC-12-0192. Print 2013 Feb.

15.

Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns.

Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, Ramsahoye BH, Meehan RR.

Genome Biol. 2012 Oct 3;13(10):R84. doi: 10.1186/gb-2012-13-10-r84.

16.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
17.

Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.

Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, Sims AH.

BMC Med Genomics. 2012 Aug 21;5:35. doi: 10.1186/1755-8794-5-35.

18.

The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells.

Wang B, Lindley LE, Fernandez-Vega V, Rieger ME, Sims AH, Briegel KJ.

PLoS One. 2012;7(7):e41355. doi: 10.1371/journal.pone.0041355. Epub 2012 Jul 23.

19.

Targeting of Rac GTPases blocks the spread of intact human breast cancer.

Katz E, Sims AH, Sproul D, Caldwell H, Dixon MJ, Meehan RR, Harrison DJ.

Oncotarget. 2012 Jun;3(6):608-19.

20.

KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.

Moleirinho S, Chang N, Sims AH, Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy C, Faratian D, Gunn-Moore FJ, Reynolds PA.

Oncogene. 2013 Apr 4;32(14):1821-30. doi: 10.1038/onc.2012.196. Epub 2012 May 21.

PMID:
22614006
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk